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Abstract Human neutrophils constitutively undergo apoptosis
and this process is critical for the resolution of inflammation.
Whilst neutrophil apoptosis can be modulated by a wide variety
of agents including GM-CSF, LPS and TNF-K, the molecular
mechanisms underlying neutrophil death and survival remain
largely undefined. Recent studies have shown the involvement of
members of the Bcl-2 protein family (especially Mcl-1 and A1)
and caspases in the regulation and execution of neutrophil
apoptosis. Cell surface receptors and protein kinases, particu-
larly mitogen-activated protein kinases, also play critical roles in
transducing the signals that result in neutrophil apoptosis or
extended survival. This review summarises current knowledge on
the molecular mechanisms and components of neutrophil
apoptosis. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Neutrophils are polymorphonuclear leukocytes that are es-
sential components of the natural immune system. They form
the ¢rst line of defence against bacterial and fungal infections.
Neutrophils are terminally di¡erentiated cells and are pro-
duced in the bone marrow from myeloid stem cells by the
process called ‘phagocytopoiesis’. Whilst they have a very
short half life in the circulation (8^20 h), this can increase
several fold once they enter infected or in£amed tissues [1].
Aged neutrophils undergo spontaneous apoptosis (pro-
grammed cell death) in the absence of cytokines or other
proin£ammatory agents prior to their removal by macro-
phages [2]. This phagocytic removal of intact, apoptotic neu-
trophils prevents them from releasing their cytotoxic content
into the extracellular milieu that would occur if the cells died
by necrosis. In acute in£ammation, neutrophil numbers within
tissues can be extremely high because of targeted in£ux from
the circulation and because their constitutive apoptotic path-
way is delayed by the action of local in£ammatory mediators
[3]. Thus, the potential for in£ammatory neutrophils to cause
tissue damage via the release of toxic reactive oxygen species
and granule enzymes such as proteases is very high. Death by
apoptosis and safe removal by phagocytic cells thus helps to
limit tissue damage during the resolution of in£ammation.
Understanding the processes that regulate constitutive neutro-
phil apoptosis and cytokine-mediated delay of cell death will
lead to a better understanding of the molecular pathology of
in£ammatory diseases in which neutrophil apoptosis may be
perturbed and could also identify new therapeutic targets.
2. Molecular changes in neutrophils during apoptosis
Neutrophils lose their functional properties during apopto-
sis and they display morphological and biochemical character-
istics of an apoptotic cell, including cell shrinkage, compac-
tion of chromatin and loss of the multilobed shape of the
nucleus [4^6]. They also show molecular alterations on their
cell surface that result from either decreased expression of
certain receptors or else the appearance of new surface mole-
cules. Neutrophil apoptosis is accompanied by the down-reg-
ulation of the immunoglobulin superfamily members (e.g.
CD31, CD50, CD66acde, CD66b, CD63 and CD87) and
cell surface receptors (e.g. CD15, CD16, CD32, CD35,
CD88, CD120b [8,9]). Phosphatidylserine, a molecular marker
of apoptotic cells, also appears on the surface of apoptotic
neutrophils as the symmetry of their plasma membrane phos-
pholipids is altered [9,10]. The externalisation of this molecule
facilitates the recognition of apoptotic neutrophils by macro-
phages and it is also a convenient indicator of apoptotic neu-
trophils as phosphatidylserine can bind £uorescently labelled
annexin V [11].
Apoptotic neutrophils are non-functional and lose the abil-
ity to move by chemotaxis, generate a respiratory burst or
degranulate. This loss of functional capacity results from the
disablement of their activation pathways, and the decreased
expression of surface receptors aids in this shutdown in activ-
ity by preventing them e⁄ciently binding extracellular ligands.
These inactive neutrophils, with altered surface epitopes, are
then phagocytosed [4,5]. Fibroblasts ingesting apoptotic neu-
trophils employ both KvL3 and lectin-like receptors, which
may recognise the changes in the carbohydrate moieties on
the surface of apoptotic cells. The phagocyte adhesion mole-
cule CD36 co-operates with KvL3 to bind thrombospondin
(TSP) that is secreted by phagocytes. TSP may function as a
bridge between the phagocyte receptors and unknown struc-
tures on the surface of apoptotic neutrophils.
The two key questions that need to be addressed are: ‘what
processes control this high rate of constitutive neutrophil ap-
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optosis?’ and ‘how is this constitutive apoptotic pathway
regulated by external factors?’
3. Extracellular modulators of neutrophil apoptosis and survival
A number of in vitro studies have demonstrated that several
factors can accelerate or suppress neutrophil apoptosis. It has
been reported that in£ammatory cytokines including IL-1L,
IL-2, TNF-K, IL-15, INF-Q, G-CSF, GM-CSF and LPS can
prolong neutrophil survival [1^18]. The reported e¡ects of IL-
6 on neutrophil apoptosis are variable [19,20]. IL-8, a chemo-
kine, has also been shown to delay neutrophil apoptosis medi-
ated by Fas and TNF-K receptors [21,22]. Neutrophils are
susceptible to Fas-induced apoptosis and an interaction be-
tween Fas and Fas ligand (FasL) was originally suggested to
represent a mechanism to explain constitutive neutrophil ap-
optosis [23]. Neutrophils express signi¢cant levels of Fas and
whilst early reports indicated that they could also express
FasL [23], this ¢nding has not been con¢rmed in later reports
[24,25]. Neutrophils from CD95 de¢cient mice (lacking Fas)
undergo constitutive or spontaneous apoptosis at the same
rate as control mice, arguing against a role for the Fas system
in constitutive apoptosis [26,27]. In addition, only aggregated
or membrane bound FasL, rather than soluble (S)FasL, can
induce apoptosis. Recently, SFasL has also been reported to
induce neutrophil chemotaxis, rather than apoptosis [28].
Hence, the role of the Fas/FasL system in regulation of neu-
trophil apoptosis in in£ammation and disease is still contro-
versial.
TNF-K has been variably reported to induce, delay or have
no e¡ect on neutrophil apoptosis. It has been shown that
while prolonged incubations (s 12 h) of human neutrophils
with TNF-K can cause a decrease in apoptosis, TNF-K can
also induce apoptosis in a sub-population of cells at earlier
times of incubation (6 8 h) [29]. TNF-K may thus rapidly
activate a death pathway in susceptible cells, but stimulate
an anti-apoptotic pathway in the surviving cells (see later).
It has also been shown that signals triggered in neutrophils
via ligation of their adhesion receptors can modify their life-
span [30]. Similarly, a role of endothelial transmigration in the
regulation of neutrophil apoptosis has been reported again
indicating that adhesion molecules can generate intracellular
signals that trigger enhanced survival of neutrophils as they
migrate from the bloodstream into tissues [31].
In contrast to observations in other cell types, hypoxia de-
lays apoptosis in human neutrophils [32]. Furthermore, some
antioxidants (e.g. catalase) but not others (e.g. superoxide
dismutase) can delay apoptosis when neutrophils are incu-
bated under normoxic conditions. In addition, neutrophils
from patients with chronic granulomatous disease (which
have an impaired capacity to generate reactive oxygen metab-
olites because of a defect in their NADPH oxidase) have
delayed apoptosis in vitro [33]. Thus, exogenous or neutro-
phil-derived oxidants can promote neutrophil apoptosis. This
phenomenon may be important in the function of these cells
during in£ammation. When recruited into tissues, neutrophils
move from normoxic to hypoxic conditions, and hence de-
creased O2 tensions at in£ammatory sites may extend their
life-span. However, if they are activated to secrete large quan-
tities of reactive oxygen metabolites then this may promote
their apoptosis and subsequent removal by other professional
phagocytes.
Cycloheximide and actinomycin D (inhibitors of translation
and transcription, respectively) both accelerate neutrophil ap-
optosis in vitro [34,35]. This observation, together with the
¢nding that agents that delay neutrophil apoptosis (e.g. cyto-
kines and glucocorticoids such as dexamethasone, [36]) invar-
iably also stimulate protein biosynthesis, leads to the conclu-
sion that neutrophil survival may be regulated by the
expression of transiently expressed protein(s). Thus, agents
that regulate neutrophil death and survival may do so by
altering the activity of pre-existing proteins (e.g. via phos-
phorylation reactions) or may regulate signalling pathways
that lead to the activation of speci¢c transcription factors
that induce the expression of key genes.
4. Regulation of neutrophil apoptosis and survival
As is the case in many other cell types, the execution of the
apoptotic pathway in neutrophils is mediated by the caspases.
Neutrophils have been reported to express a variety of regu-
latory and e¡ector caspases, including caspases-1, -3, -4 and -8
Table 1
Expression of Bcl-2 family proteins in human neutrophils
Ref. Bcl-2 Bcl-XL Mcl-1 A1 Bcl-w Bax Bad Bak Bik
[38] 3 (R) 3 (R) + (R) + (R) 3 (R) + (R) + (R) 3 (R)
[59] 3 (R) + (R) + (R) + (R)
+ (W) + (W) 3 (W)
[60] 3 (W) 3 (W) 3 (W) + (W)
[6] 3 (W) 3 (W) + (W) + (W)
[61] + (I)
[62] + (F)
[63] 3 (F) + (F)
[64] + (I)
[55] + (RP) + (N,RP)
[65] + (N,W)
[66] 3 (F) + (F) + (F, W)a
3 (F, W)b
[67] + (W)
[68] + (W)
3 represents no reported expression, whilst + represents expression. The detection methods are as follows: R, RT-PCR; W, Western blotting;
F, £ow cytometry; RP, RNase protection; I, immuno-£uorescence; N, Northern blotting.
aExpression reported in control neutrophils.
bExpression reported in in£ammatory neutrophils.
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[37,38]. Neutrophils also express a number of the Bcl-2 family
of proteins (Table 1), but there are some discrepancies and
ambiguities in the literature, largely because of the use of a
variety of di¡erent methods to detect expression. It is now
generally agreed that human neutrophils do not express the
anti-apoptotic protein Bcl-2 but they constitutively express the
pro-apoptotic proteins Bax, Bid, Bak and Bad. These proteins
have a relatively long half life and hence their constitutive
expression helps explain why bloodstream neutrophils have
such a short survival time in the absence of Bcl-2 expression.
Human neutrophils do express mRNA for the anti-apopto-
tic proteins, Mcl-1, A1 and Bcl-XL, but only convincing evi-
dence for the expression of Mcl-1 protein has been obtained
[6]. No antibodies are yet available that can reliably detect
human A1 protein and expression of Bcl-XL protein is de-
bated. Mcl-1 protein is expressed in bloodstream neutrophils
and its levels decrease prior to the onset of apoptosis [6].
Treatment of neutrophils with agents that delay apoptosis
either increases or maintains Mcl-1 levels, providing a mech-
anism to explain cytokine-mediated increased survival via en-
hanced expression of an anti-apoptotic protein. Mcl-1 mRNA
and protein (and A1 mRNA) have very short half lives (ap-
proximately 2^3 h, unpublished) whereas the half lives of the
pro-apoptotic proteins are relatively long. Hence, neutrophil
apoptosis may be governed by the cellular levels of the rela-
tively short-lived survival proteins, Mcl-1 and A1. In the ab-
sence of de novo synthesis of Mcl-1 and A1, the activity of the
longer lived pro-apoptotic proteins will predominate and ap-
optosis will ensue. However, in the presence of survival signals
(e.g. cytokines) the enhanced expression of the anti-apoptotic
proteins will ensure survival.
It is thus necessary to identify the intracellular signalling
pathways that control expression of A1 and Mcl-1 and to
determine if the expression of these two survival proteins is
controlled by separate or overlapping signalling systems. If
transcription of A1 and Mcl-1 is regulated by separate mech-
anisms, then the possibility exists for the expression of these
two survival proteins to be modulated by di¡erent extracellu-
lar signals under di¡erent patho-physiological conditions.
5. Signalling pathways leading to neutrophil apoptosis
In spite of the fact that it has been realised for many years
that cytokines and other agents can modulate neutrophil ap-
optosis, the intracellular signalling pathways that control this
process are still largely unknown (Fig. 1). It is clear that phos-
phorylation cascades, involving phosphorylation on tyrosine,
serine and threonine residues, may be important. Agents that
elevate cAMP levels delay apoptosis in neutrophils via protein
kinase A activity [39] and protein kinase C (PKC) activity, in
particular PKC-N, has also been implicated in constitutive ap-
optosis of neutrophils [40]. However, the downstream targets
of these kinases have not been fully identi¢ed.
It has been demonstrated that GM-CSF, TNF-K and LPS
increase the tyrosine phosphorylation of a number of proteins,
including the isoforms of mitogen-activated protein kinases
(MAPKs) [41,42]. MAPKs are extracellular signal-regulated
protein kinases that are important mediators of signal trans-
duction pathways regulated by many types of cell surface
receptors. Phosphorylation of proteins on tyrosine residues,
including activation of MAPK, may thus be important in
controlling the activation of the various neutrophil processes
required for their function in host defence, but may also be
important in the pathways regulating neutrophil cell death
and survival.
There are three major types of MAPKs in mammalian cells:
p42/44 extracellular signal-related protein kinase (ERK)
(which are activated by phosphorylated MEK), p38MAPK
and c-Jun N-terminal kinase/stress-activated MAPK (which
are generally activated by stresses, such as irradiation and
hyperosmolarity). Whilst all three types of MAPK have
been detected in human neutrophils, supporting evidence
(generally via detection of the active forms of these kinases
using antibodies that only bind the phosphorylated proteins in
Western blots) for only ERK and p38MAPK in neutrophil
apoptosis has been reported. Additionally, the functional role
of these kinases can be probed with the use of inhibitors:
PD98059 (which inhibits MEK, thereby preventing the phos-
phorylation and activation of ERK), and SB902190 and
SB203580 which are used to inhibit p38MAPK.
There has been much interest in the role of p38MAPK in
the regulation of neutrophil apoptosis and survival. Whilst
experiments using inhibitors and antisense technology indi-
cated a role for p38MAPK in constitutive apoptosis of neu-
trophils [43], this ¢nding has not been con¢rmed in other
reports [27,44]. Cellular stresses (such as hyperosmolarity or
irradiation) clearly stimulated p38MAPK activity and accel-
erated apoptosis [44]. However, some factors that either de-
layed (GM-CSF) or accelerated apoptosis (anti-Fas antibod-
ies) have been reported not to a¡ect the activation status of
p38MAPK [43]. The role of p38MAPK is further complicated
by the report that hypoxia-mediated delay of apoptosis re-
quires p38MAPK activity [45] whereas LPS delayed apoptosis
is enhanced when p38MAPK activity is inhibited [46]. The
Fig. 1. Possible roles of MAPKs and PI3K in neutrophil apoptosis
and survival. Acceleration of neutrophil apoptosis, e.g. via stress,
may involve the generation of death signals via the activity of
p38MAPK. In the presence of survival signals (e.g. cytokines or
LPS) p38MAPK kinase may still be active, but signals generated
via activated ERK and PI3K may override or inhibit the
p38MAPK death signal, and so neutrophil apoptosis is delayed. It
has, however, been reported that hypoxia-mediated activation of
p38MAPK may result in the generation of a survival signal [45].
The survival signals may include phosphorylation (e.g. inactivation
of Bad), and/or activation of transcription factors that up-regulate
expression of the survival proteins, A1 and Mcl-1. Other signalling
pathways and intermediary components of these signalling systems
are likely to exist. Sites of action of inhibitors used to probe func-
tion are shown in italics.
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role of p38MAPK in the control of neutrophil apoptosis and
survival is therefore unclear. Perhaps divergent signals gener-
ated downstream of p38MAPK activation can control either
cell death or survival or perhaps survival signals generated
from other systems (e.g. ERK, see below) can modulate the
death signal generated by p38MAPK (Fig. 1).
Clear evidence is emerging that ERK activity results in the
generation of survival signals. GM-CSF has been shown to
increase the activity of ERK and to delay apoptosis [47],
presumably via activation of Lyn kinase [48]. Furthermore,
apoptosis delaying agents (such as GM-CSF and IL-8) can
additionally activate phosphoinositide 3-kinase (PI3K) [47]
and this activation is also associated with the generation of
survival signals that can override the p38MAPK death signals
[44]. However, the survival signals generated by PI3K may be
di¡erent to those generated by ERK. PI3K can activate
(phosphorylate) Akt, which in turn may phosphorylate Bad,
thereby decreasing its pro-apoptotic e¡ects [47].
This multiplicity of the pro- and anti-apoptotic signals gen-
erated by activated MAPKs may also help explain the di¡er-
ential e¡ects of cytokines on neutrophil survival. For example,
G-CSF was shown to strongly activate ERK (via MEK)
whereas GM-CSF strongly activated ERK and but only
weakly activated p38MAPK [49]. These cytokines will thus
both generate survival signals. These MAPKs may also be
responsible, at least in part, for the inhibition of constitutive
apoptosis seen during incubation under hypoxia. Experiments
using PD98059 and SB202190 showed that ERK and
p38MAPK, respectively, were involved in regulating hypox-
ia-mediated delay of apoptosis [45]. This delay of apoptosis
was associated with increased expression of the survival pro-
tein, Mcl-1, which suggests that hypoxia-induced expression
of this protein is regulated by the activity of these kinases.
The e¡ects of TNF on neutrophils are complicated by the
fact that this agent rapidly accelerates apoptosis in a sub-
population of cells, but generates an anti-apoptotic signal in
the remaining cells [29]. TNF-K was shown to strongly acti-
vate p38MAPK [49] which may generate a death signal in the
sub-population of neutrophils that are susceptible to this
agent. It must also be pointed out that ligation of TNF-K
with its receptor can activate caspase-8, which in turn acti-
vates a caspase cascade that can also generate strong death
signals [50,51]. In contrast, the survival signals generated by
TNF-K in the sub-population of neutrophils that are not ini-
tially killed by this cytokine may be mediated via enhanced
transcription of survival proteins via activation of the tran-
scription factor, NFUB [52]. Thus, under certain circumstan-
ces, NFUB-regulated gene products may be important in cy-
tokine-mediated neutrophil survival [53].
A1 has been shown to be a gene whose expression is regu-
lated by NFUB in other cell systems [54]. A1 mRNA is con-
stitutively expressed in human neutrophils and its expression
can be further enhanced by GM-CSF, LPS and TNF-K and
by phagocytic stimuli [55]. However, not all agents that delay
neutrophil apoptosis can activate NFUB [52,56]. Indeed, GM-
CSF, which is a potent delayer of neutrophil apoptosis, does
not generate signals leading to NFUB activation. Further-
more, whilst the A1 gene has clearly identi¢able consensus
NFUB binding motifs [57], the human mcl-1 gene does not
appear to be regulated by NFUB [58]. Clearly, in human neu-
trophils, there appear to be NFUB-dependent and -independ-
ent signalling pathways leading to delay of apoptosis via acti-
vated gene expression.
6. Concluding remarks
The high rate of constitutive apoptosis that is a special
feature of human neutrophils may be explained, at least in
part, by the constitutive expression of a range of pro-apopto-
tic proteins of the Bcl-2 family. Extended survival that is
mediated by cytokines or other exogenous factors appears
to involve the inducible expression of the survival proteins
A1 and Mcl-1, via pathways that involve activated transcrip-
tion. Promoter studies indicate that separate transcriptional
signalling pathways that involve NFUB and MAPKs regulate
the expression of these two proteins. This raises the possibility
that these signalling pathways may be independently regulated
by di¡erent exogenous signals. It will therefore be an impor-
tant challenge to identify the signalling systems that are acti-
vated in diseases in which neutrophil apoptosis and survival
are intimately involved in pathology.
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